Alnylam Pharmaceuticals | ALNY - Gross Profit On Sales

Stock Price
294.53
Daily Change
8.26 2.89%
Monthly
-5.28%
Yearly
0.98%
Q2 Forecast
281.21

Alnylam Pharmaceuticals reported $825M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Amgen USD 6.89B 415M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 10.82B 694M Sep/2025
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Takeda JPY 688.84B 101.71B Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xencor USD 21M 22.61M Sep/2025